tiprankstipranks
Trending News
More News >
Kilitch Drugs (India) Limited (IN:KILITCH)
:KILITCH
India Market

Kilitch Drugs (India) Limited (KILITCH) Price & Analysis

Compare
0 Followers

KILITCH Stock Chart & Stats

₹355.60
₹0.95(0.27%)
At close: 4:00 PM EST
₹355.60
₹0.95(0.27%)

Bulls Say, Bears Say

Bulls Say
Diversified Manufacturing And Export Business ModelKilitch's mix of domestic finished formulations, exports and third-party manufacturing creates multiple, durable revenue channels. Contract manufacturing smooths capacity utilization and revenue visibility, while exports diversify geographic risk, supporting stable cash generation and resilience over months.
Consistent Revenue GrowthSustained ~14% revenue growth indicates expanding demand and commercial momentum across product lines. That trend supports scale advantages, strengthens negotiating leverage with suppliers/customers, and underpins longer-term margin improvement if maintained over the next several quarters.
Improving Profitability MetricsReported improvement in gross and net margins, alongside strong EPS growth, signals better cost control and pricing power. Higher margins enhance cash earnings potential and provide buffer against industry price pressure, improving long-term reinvestment and shareholder return prospects.
Bears Say
Weak Free Cash Flow And Cash ConversionNegative free cash flow and strained cash conversion limit Kilitch's financial flexibility to fund capex, scale manufacturing, or return capital without external financing. Over months this can pressure liquidity, raise financing costs, or force prioritization between growth and balance sheet repair.
Moderate Operating Efficiency (EBIT/EBITDA)Persistently moderate EBIT/EBITDA margins suggest limited operational leverage and vulnerability to raw material or pricing shocks. Without efficiency gains, margin expansion may stall, constraining cash flow generation and reducing the company's ability to finance growth internally over the medium term.
Suboptimal Asset Utilization Despite Strong EquityA sturdy equity base with room to optimize ROE points to underutilized assets or capital. If management doesn't improve asset turnover or capital allocation, returns on invested capital may lag, limiting long-term shareholder value creation even with a healthy balance sheet.

KILITCH FAQ

What was Kilitch Drugs (India) Limited’s price range in the past 12 months?
Kilitch Drugs (India) Limited lowest stock price was ₹265.50 and its highest was ₹490.00 in the past 12 months.
    What is Kilitch Drugs (India) Limited’s market cap?
    Kilitch Drugs (India) Limited’s market cap is ₹5.51B.
      When is Kilitch Drugs (India) Limited’s upcoming earnings report date?
      Kilitch Drugs (India) Limited’s upcoming earnings report date is May 27, 2026 which is in 65 days.
        How were Kilitch Drugs (India) Limited’s earnings last quarter?
        Kilitch Drugs (India) Limited released its earnings results on Feb 11, 2026. The company reported ₹2.536 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.536.
          Is Kilitch Drugs (India) Limited overvalued?
          According to Wall Street analysts Kilitch Drugs (India) Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Kilitch Drugs (India) Limited pay dividends?
            Kilitch Drugs (India) Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Kilitch Drugs (India) Limited dividends here
              What is Kilitch Drugs (India) Limited’s EPS estimate?
              Kilitch Drugs (India) Limited’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Kilitch Drugs (India) Limited have?
              Kilitch Drugs (India) Limited has 17,480,782 shares outstanding.
                What happened to Kilitch Drugs (India) Limited’s price movement after its last earnings report?
                Kilitch Drugs (India) Limited reported an EPS of ₹2.536 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.637%.
                  Which hedge fund is a major shareholder of Kilitch Drugs (India) Limited?
                  Currently, no hedge funds are holding shares in IN:KILITCH
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Kilitch Drugs (India) Limited

                    Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

                    Kilitch Drugs (India) Limited (KILITCH) Earnings & Revenues

                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Ind-Swift Laboratories Ltd.
                    Medicamen Biotech Limited
                    Nectar Lifesciences Ltd.
                    Sakar Healthcare Ltd
                    Venus Remedies Limited
                    Popular Stocks